Improving resource utilisation in SLE drug development through innovative trial design

Autor: Joan T Merrill, Kenneth Kalunian, Sandra Garces, Anca D Askanase, Elaine Karis, May Mo, Cassandra E Milmont

Publikováno v: Lupus Science and Medicine, Vol 10, Iss 2 (2023)

SLE is a complex autoimmune disease with considerable unmet need. Numerous clinical trials designed to investigate novel therapies are actively enrolling patients straining limited resources and creating inefficiencies that increase enrolment challen

Externí odkaz: https://doaj.org/article/2fa9074c62ef463690b0a0c71f60cdae

Romosozumab and antiresorptive treatment: the importance of treatment sequence

Autor: Felicia Cosman, David L. Kendler, Bente L. Langdahl, Benjamin Z. Leder, E. Michael Lewiecki, Akimitsu Miyauchi, Maria Rojeski, Michele McDermott, Mary K. Oates, Cassandra E. Milmont, Cesar Libanati, Serge Ferrari

Publikováno v: Cosman, F, Kendler, D L, Langdahl, B L, Leder, B Z, Lewiecki, E M, Miyauchi, A, Rojeski, M, McDermott, M, Oates, M K, Milmont, C E, Libanati, C & Ferrari, S 2022, ' Romosozumab and antiresorptive treatment : the importance of treatment sequence ', Osteoporosis International, vol. 33, no. 6, pp. 1243-1256 . https://doi.org/10.1007/s00198-021-06174-0

Summary: To evaluate whether treatment sequence affects romosozumab response, this analysis reviewed studies where romosozumab was administered before or following an antiresorptive (alendronate or denosumab). Initial treatment with romosozumab follo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e94e72c5c5eae6312e53d45028a2072b
https://doi.org/10.1007/s00198-021-06174-0

One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study

Autor: Peter R. Ebeling, Evelien Gielen, Cesar Libanati, Akimitsu Miyauchi, Jonathan D. Adachi, Rajani Dinavahi, Marise Lazaretti-Castro, Cassandra E Milmont, Andreas Grauer, E. Michael Lewiecki

Publikováno v: Journal of Bone and Mineral Research. 34:419-428

Romosozumab, a humanized monoclonal antibody that binds and inhibits sclerostin, has the dual effect of increasing bone formation and decreasing bone resorption. As previously reported in the pivotal FRActure study in postmenopausal woMen with ostEop

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a79567cf6590eba9a503fbc8c0b47dc2
https://doi.org/10.1002/jbmr.3622

Correction to: Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial

Autor: Junichi Takada, Rajani Dinavahi, Akimitsu Miyauchi, Etsuro Hamaya, Toshiyasu Hirama, Cesar Libanati, Yoichi Nakamura, Cassandra E. Milmont, Andreas Grauer

Publikováno v: Journal of bone and mineral metabolism. 38(4)

In the original publication of the article, the last row of Table 1 was published incorrectly as "Serum P1NP (μmol/L), median (IQR)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3fcbb88e4a2a9e732d745939dab60e3
https://pubmed.ncbi.nlm.nih.gov/31707465

OP0344 Frame study: the foundation effect of rebuilding bone with one year of romosozumab leads to continued lower fracture risk after transition to denosumab

Autor: Toshio Matsumoto, Daria B. Crittenden, Nancy E Lane, Aliya Khan, Felicia Cosman, Kurt Lippuner, Cassandra E Milmont, Cesar Libanati, Andreas Grauer, Serge Ferrari

Publikováno v: FRIDAY, 15 JUNE 2018.

Objectives Romosozumab (Romo), a sclerostin antibody, has a dual effect of increasing bone formation and decreasing bone resorption. In the FRAME study (NCT01575834), one year of Romo treatment resulted in large bone mineral density (BMD) increases a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::75258cb358c1a56b94493e55e557aa5c
https://doi.org/10.1136/annrheumdis-2018-eular.2891